UNSPSC 51434927: Diltiazem/enalapril

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434927 Diltiazem/enalapril is a Commodity code that represents specific pharmaceutical products procured by state and local governments for emergency medical and healthcare delivery. State and local buyers under this code are acquiring emergency medications and generic pharmaceuticals for fire rescue operations, state health agencies, and cooperative purchasing programs serving multiple jurisdictions. The City of Tampa's Fire Rescue, the Texas Health and Human Services Commission, and multistate cooperative purchasing alliances such as MMCAP represent the range of issuing bodies—municipal emergency services, state health authorities, and collaborative procurement vehicles that aggregate demand across participating states and local governments. The work being solicited includes supply agreements for branded or generic cardiac and hypertensive medications (diltiazem, enalapril, and related agents) in specified strengths and packaging, alongside broader generic pharmaceutical and OTC product contracts where these specific drugs may be included in larger product catalogs. Vendors must meet pharmaceutical manufacturing compliance (cGMP, DSCSA, FDA approval), maintain expiration-date and shelf-life standards, and provide Safety Data Sheets and accessibility documentation as required by federal and state standards.

Recent activity is distributed across Florida, Texas, and Minnesota. The City of Tampa posted an IFB (Bid No. 26-P-00188) on April 24, 2026, seeking Advanced Life Support Medications including 1,020 units of diltiazem 25mg vials for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, indicating exploratory procurement that may lead to a future RFP. The Minnesota Department of Administration, on behalf of MMCAP, posted an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) across participating state and local facilities including Oregon, with awards effective July 1, 2026, and a contract term of two years.